Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
By Sabela Ojea
Shares of Rocket Pharmaceuticals surged 34% to $20.46 in post-market trading on Tuesday after the company said it reached alignment with the Food and Drug Administration regarding its Phase 2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of the investigational gene therapy RP-A501 to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known for weakening the heart and movement muscles, as well as intellectual disability.
The trial will support accelerated approval of Rocket's treatment by the FDA.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:13 ET (21:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks